Dolomite Bio Maintains Rapid Growth Trajectory and Launches Novel Products throughout 2018

Dolomite Bio, part of the Blacktrace group, is helping to drive forward the single cell genomics revolution. Single cell analysis promises to transform drug discovery and disease research, enabling scientists to investigate cell diversity and quantify gene expression at the cellular level. This up and coming market sector is forecast to be worth $5.9bn by 2025*, with revenue growth driven by an increasing demand for...

More From BioPortfolio on "Dolomite Bio Maintains Rapid Growth Trajectory and Launches Novel Products throughout 2018"